Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
BJU Int. 2020 Jan;125(1):38-48. doi: 10.1111/bju.14888. Epub 2019 Sep 25.
To examine the effect of non-muscle-invasive bladder cancer (NMIBC) diagnosis and treatment on survivors' quality of life (QoL).
Of the 5979 patients with NMIBC diagnosed between 2010 and 2014 in North Carolina, 2000 patients were randomly selected to be invited to enroll in this cross-sectional study. Data were collected by postal mail survey. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core (QLQ-C30) and the NMIBC-specific module were included in the survey to measure QoL. Descriptive statistics, t-tests, anova, and Pearson's correlation were used to describe demographics and to assess how QoL varied by sex, cancer stage, time since diagnosis, and treatment.
A total of 398 survivors returned questionnaires (response rate: 23.6%). The mean QoL score for QLQ-C30 (range 0-100, higher = better QoL in all domains but symptoms) for global health status was 73.6, function domain scores ranged from 83.9 to 86.5, and scores for the top five symptoms (insomnia, fatigue, dyspnoea, pain, and financial difficulties) ranged from 14.1 to 24.3. The lowest NMIBC-specific QoL domain was sexual issues including sexual function, enjoyment, problems, and intimacy. Women had worse bowel problems, sexual function, and sexual enjoyment than men but better sexual intimacy and fewer concerns about contaminating their partner. Stage Ta had the highest global health status, followed by T1 and Tis. QoL did not vary by time since diagnosis except for sexual function. The cystectomy group (n = 21) had worse QoL in sexual function, discomfort with sexual intimacy, sexual enjoyment, and male sexual problems than the non-cystectomy group (n = 336).
Survivors of NMIBC face a unique burden associated with their diagnosis and the often-lifelong surveillance and treatment regimens. The finding has important implications for the design of tailored supportive care interventions to improve QoL for NMIBC survivors.
探讨非肌层浸润性膀胱癌(NMIBC)诊断和治疗对患者生存质量(QoL)的影响。
在北卡罗来纳州 2010 年至 2014 年间诊断的 5979 例 NMIBC 患者中,随机选择 2000 例患者邀请参加这项横断面研究。通过邮寄问卷进行数据收集。调查包括欧洲癌症研究和治疗组织生存质量核心问卷(QLQ-C30)和 NMIBC 特异性模块,以测量 QoL。采用描述性统计、t 检验、方差分析和 Pearson 相关分析来描述人口统计学特征,并评估 QoL 如何因性别、癌症分期、诊断后时间和治疗方式的不同而变化。
共有 398 名幸存者返回了问卷(应答率:23.6%)。QLQ-C30 的全球健康状况平均 QoL 得分为 73.6(范围 0-100,所有领域得分越高表示 QoL 越好,但症状除外),功能域得分范围为 83.9 至 86.5,前五个症状(失眠、疲劳、呼吸困难、疼痛和经济困难)得分范围为 14.1 至 24.3。NMIBC 特异性 QoL 领域中得分最低的是性问题,包括性功能、性享受、问题和亲密关系。女性的肠道问题、性功能和性享受比男性差,但性亲密感更好,对感染伴侣的担忧更少。Ta 期的全球健康状况最好,其次是 T1 期和Tis 期。除了性功能外,QoL 与诊断后时间无关。与非膀胱切除术组(n=336)相比,膀胱切除术组(n=21)的性功能、性亲密不适、性享受和男性性功能问题的 QoL 更差。
NMIBC 患者面临与诊断以及长期的监测和治疗方案相关的独特负担。这一发现对设计有针对性的支持性护理干预措施以提高 NMIBC 幸存者的 QoL 具有重要意义。